Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29898831 | 1.00 | KAT6A (0.32) | KAT6ACYP3A4ADRB1ADRA2AADRB3 | |
| SCHEMBL26982032 | 0.85 | CES2 (0.39) | CYP3A4ADRB1ADRA2AADRB3ADRA2B | |
| SCHEMBL6712716 | 0.80 | CYP3A4 (0.40) | CYP3A4NPSR1 | |
| SCHEMBL933311 | 0.79 | APLNR (0.36) | KAT6AHPGDTSHR | |
| SCHEMBL14633329 | 0.77 | F2R (0.36) | KAT6AHPGDTSHRNPSR1 | |
| SCHEMBL29896649 | 0.76 | IDO1 (0.39) | CYP3A4HPGDALOX15TSHR | |
| SCHEMBL933759 | 0.76 | IDO1 (0.39) | CYP3A4HPGDALOX15TSHR | |
| SCHEMBL14830608 | 0.76 | CHRM2 (0.40) | TSHR | |
| SCHEMBL2474310 | 0.74 | L3MBTL1 (0.34) | HPGDTSHR | |
| SCHEMBL26982178 | 0.74 | CES2 (0.37) | CYP3A4ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-4301745-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | King's College London (GB) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022185055-A1 | PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS | KING'S COLLEGE LONDON (GB) | 2022-09-09 | — | — | WO | disclosed |
| US-8637551-B2 | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-28 | — | — | US | disclosed |
| EP-2473489-B1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-08-21 | — | — | EP | disclosed |
| US-20130023566-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | N.V. ORGANON (NL) | 2013-01-24 | — | — | US | disclosed |
| EP-2473489-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | MSD Oss B.V. (NL) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011003895-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | N.V. ORGANON (NL) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023566-A1 | 2-(1,2-BENZISOXAZOL-3-YL)BENZYLAMINE DERIVATIVES | CNR2, CNR1, OPRL1 | KAT6A 3476/4885CYP3A4 438/4885ADRB1 196/4885 |
| US-20240190854-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | HCN2, HCN1, HCN3 | KAT6A 3494/4885CYP3A4 1940/4885ADRB1 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.